Toward innovative veterinary nanoparticle vaccines
-
Published:2024-05-10
Issue:1
Volume:4
Page:
-
ISSN:2731-0442
-
Container-title:Animal Diseases
-
language:en
-
Short-container-title:Animal Diseases
Author:
Sun Meiqi,Pratama Aldryan Cristianto,Qiu He,Liu Zehui,He Fang
Abstract
AbstractNanoparticles are significant for veterinary vaccine development because they are safer and more effective than conventional formulations. One promising area of research involves self-assembled protein nanoparticles (SAPNs), which have shown potential for enhancing antigen-presenting cell uptake, B-cell activation, and lymph node trafficking. Numerous nanovaccines have been utilized in veterinary medicine, including natural self-assembled protein nanoparticles, rationally designed self-assembled protein nanoparticles, animal virus-derived nanoparticles, bacteriophage-derived nanoparticles, and plant-derived nanoparticles, which will be discussed in this review. SAPN vaccines can produce robust cellular and humoral immune responses and have been shown to protect against various animal infectious diseases. This article attempts to summarize these diverse nanovaccine types and their recent research progress in the field of veterinary medicine. Furthermore, this paper highlights their disadvantages and methods for improving their immunogenicity.
Publisher
Springer Science and Business Media LLC
Reference170 articles.
1. Abrams, C.C., A.M. King, and G.J. Belsham. 1995. Assembly of foot-and-mouth disease virus empty capsids synthesized by a vaccinia virus expression system. J Gen Virol 76 (Pt 12): 3089–3098. https://doi.org/10.1099/0022-1317-76-12-3089. 2. Al-Barwani, F., S.L. Young, M.A. Baird, D.S. Larsen, and V.K. Ward. 2014. Mannosylation of virus-like particles enhances internalization by antigen presenting cells. PLoS One 9: e104523. https://doi.org/10.1371/journal.pone.0104523. 3. Alam, M.M., Jarvis, C.M., Hincapie, R., McKay, C.S., Schimer, J., Sanhueza, C.A., Xu, K., Diehl, R.C., Finn, M.G., Kiessling, L.L. 2021. Glycan-modified virus-like particles evoke T helper type 1-like immune responses. ACS Nano 15: 309–321. https://doi.org/10.1021/acsnano.0c03023. 4. Antonis, A.F., Bruschke, C.J., Rueda, P., Maranga, L., Casal, J.I., Vela, C., Hilgers, L.A., Belt, P.B., Weerdmeester, K., Carrondo, M.J., Langeveld, JP. 2006. A novel recombinant virus-like particle vaccine for prevention of porcine parvovirus-induced reproductive failure. Vaccine 24: 5481–5490. https://doi.org/10.1016/j.vaccine.2006.03.089. 5. Anwar, M.N., Jiang, C., Di D., Zhang, J., Guo, S., Wang, X., Hameed, M., Wahaab, A., Shao, D., Li, Z., Liu, K., Li, B., Qiu, Y., Ma, Z., Wei, J. 2021. A Novel recombinant virus-Like particles displaying B and T cell epitopes of Japanese encephalitis virus offers protective immunity in mice and guinea pigs. Vaccines (Basel) 9. https://doi.org/10.3390/vaccines9090980.
|
|